Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance

作者：Ming‐Tain Lai, Meizhen Feng, Min Xu, Winnie Ngo, Tracy L. Diamond, Carey Hwang, Jay A. Grobler, Daria J. Hazuda, Ernest Asante‐Appiah · 发表于：Antimicrobial Agents and Chemotherapy · 年份：2022 · DOI：10.1128/aac.02223-21 · 被引用次数：29 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、Biochemical and Molecular Research

). DOR/ISL exhibited a higher barrier to resistance than DOR/3TC and dolutegravir (DTG)/3TC. Resistance analysis showed no emergence of substitutions at F227, an observation consistent with its ability to confer hypersusceptibility to ISL. Overall, the data demonstrate that DOR/ISL creates a 2-drug combination with a higher barrier to resistance, consistent with the reported clinical activity.